NCT05290363View on ClinicalTrials.gov

The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis

NARecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 6, 2022

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
Spondyloarthritis
Interventions
OTHER

Blood sampling

A 51 mL blood sample will be collected during the study

OTHER

synovial aspiration

If synovial aspiration is required in standard care for patients with peripheral spondylarthritis. Medical waste product will be collected for the study

Trial Locations (4)

51092

NOT_YET_RECRUITING

Hôpital Maison Blanche - Service de Rhumatologie, Reims

94000

NOT_YET_RECRUITING

Hôpital Henri-Mondor, AP-HP - Service de Rhumatologie, Créteil

Unknown

RECRUITING

Hôpital Cochin, AP-HP - Department of Dermatology B, Paris

RECRUITING

Hôpital Saint-Antoine, AP-HP - Service de Rhumatologie, Paris

Sponsors

Lead Sponsor

Institut Pasteur

Collaborators (1)

Janssen Biotech, Inc.
All Listed Sponsors
collaborator

Janssen Biotech, Inc.

INDUSTRY

lead

Institut Pasteur

INDUSTRY

NCT05290363 - The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter